Iker Ayestaran-Calero
Iker Ayestaran-Calero has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- David Barastegui
Instituto Cugat, Barcelona, Spain
2 shared publications - Lorenzo Escutia-Marí
Instituto Cugat—Quirónsalud Barcelona, Plaza Alfonso Comín 4-6, 08036 Barcelona, Spain
2 shared publications - Patricia Laiz-Boada
Instituto Cugat, Barcelona, Spain
2 shared publications - Roberto Seijas
Instituto Cugat, Barcelona, Spain
2 shared publications - Luis García Bordes
Instituto Cugat—Quirónsalud Barcelona, Plaza Alfonso Comín 4-6, 08036 Barcelona, Spain
1 shared publication - Luis García-Bordes
Instituto Cugat, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1578
Anticoagulant-Dependent Platelet Morphological Artefacts in Platelet-Rich Plasma Preparation: A Prospective Paired Study Comparing EDTA and Sodium Citrate with Implications for Orthobiologic Therapy
Background/Objectives: The anticoagulant used for blood collection is a fundamental but underexplored variable in platelet-rich plasma (PRP) preparation. Ethylenediaminetetraacetic acid (EDTA) and sodium citrate act on platelets through distinct calcium chelation mechanisms with potentially different consequences for PRP quality. Our group has previously demonstrated that biological and demographic variables independently modulate platelet composition in PRP; the present study extends this analysis to the pre-analytical anticoagulant variable. No prospective paired clinical study has systematically compared the effects of EDTA and sodium citrate on platelet morphological parameters in a real clinical setting. This study aimed to characterise these differences and evaluate their implications for orthobiologic therapy. Methods: A prospective within-subject paired-sample study was conducted at Instituto Cugat—Quirónsalud Barcelona (November 2025–April 2026). Twenty-six consecutive adult patients undergoing routine blood extraction prior to orthopaedic procedures had blood drawn simultaneously into K2-EDTA and sodium citrate (3.2%) tubes. Full haematological analysis was performed on a Sysmex XN automated analyser within 30 min. Primary outcomes were mean platelet volume (MPV), platelet distribution width (PDW), large platelet ratio (P-LCR), large platelet cell count (P-LCC), and plateletcrit (PCT). Statistical comparisons used the paired t-test or Wilcoxon signed-rank test; effect sizes were quantified as Cohen’s d. Results: Seven of eight platelet-related parameters differed significantly between anticoagulants (all p < 0.001). Compared to sodium citrate, EDTA produced systematically higher MPV (+10.1%, d = 2.81), P-LCR (+25.8%, d = 2.41), P-LCC (+24.3%, d = 1.70), PDW (+13.5%, d = 1.33), PCT (+7.3%, d = 0.78), RDW-CV (+2.0%, d = 0.83), and RDW-SD (+2.6%, d = 0.80). MPV was higher with EDTA in all 26/26 paired samples without exception. Total platelet count did not differ significantly (p = 0.135). Effect sizes for all morphological parameters were large (d ≥ 0.78). Conclusions: EDTA is associated with large, reproducible, and universal platelet morphological changes consistent with calcium chelation-induced artefact, not genuine platelet hypertrophy. These artefactual changes systematically overestimate platelet size and large platelet indices by up to 26%, with direct implications for PRP quality assessment in orthobiologic medicine. Sodium citrate should remain the anticoagulant of choice for PRP preparation. Clinicians using EDTA must recognise that morphological parameters do not reflect functional platelet capacity.
- 14 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1578
Open AccessAnticoagulant-Dependent Platelet Morphological Artefacts in Platelet-Rich Plasma Preparation: A Prospective Paired Study Comparing EDTA and Sodium Citrate with Implications for Orthobiologic Therapy
Background/Objectives: The anticoagulant used for blood collection is a fundamental but underexplored variable in platelet-rich plasma (PRP) preparation. Ethylenediaminetetraacetic acid (EDTA) and sodium citrate act on platelets through distinct calcium chelation mechanisms with potentially different consequences for PRP quality. Our group has previously demonstrated that biological and demographic variables independently modulate platelet composition in PRP; the present study extends this analysis to the pre-analytical anticoagulant variable. No prospective paired clinical study has systematically compared the effects of EDTA and sodium citrate on platelet morphological parameters in a real clinical setting. This study aimed to characterise these differences and evaluate their implications for orthobiologic therapy. Methods: A prospective within-subject paired-sample study was conducted at Instituto Cugat—Quirónsalud Barcelona (November 2025–April 2026). Twenty-six consecutive adult patients undergoing routine blood extraction prior to orthopaedic procedures had blood drawn simultaneously into K2-EDTA and sodium citrate (3.2%) tubes. Full haematological analysis was performed on a Sysmex XN automated analyser within 30 min. Primary outcomes were mean platelet volume (MPV), platelet distribution width (PDW), large platelet ratio (P-LCR), large platelet cell count (P-LCC), and plateletcrit (PCT). Statistical comparisons used the paired t-test or Wilcoxon signed-rank test; effect sizes were quantified as Cohen’s d. Results: Seven of eight platelet-related parameters differed significantly between anticoagulants (all p < 0.001). Compared to sodium citrate, EDTA produced systematically higher MPV (+10.1%, d = 2.81), P-LCR (+25.8%, d = 2.41), P-LCC (+24.3%, d = 1.70), PDW (+13.5%, d = 1.33), PCT (+7.3%, d = 0.78), RDW-CV (+2.0%, d = 0.83), and RDW-SD (+2.6%, d = 0.80). MPV was higher with EDTA in all 26/26 paired samples without exception. Total platelet count did not differ significantly (p = 0.135). Effect sizes for all morphological parameters were large (d ≥ 0.78). Conclusions: EDTA is associated with large, reproducible, and universal platelet morphological changes consistent with calcium chelation-induced artefact, not genuine platelet hypertrophy. These artefactual changes systematically overestimate platelet size and large platelet indices by up to 26%, with direct implications for PRP quality assessment in orthobiologic medicine. Sodium citrate should remain the anticoagulant of choice for PRP preparation. Clinicians using EDTA must recognise that morphological parameters do not reflect functional platelet capacity.
- 10 July 2026
- Published by Springer Nature in International Orthopaedics
- Vol. 50 (10) , 2577-2589
Patient selection refines total hip arthroplasty free survival after hip arthroscopy: an eighteen year, one thousand and fifty one hip cohort study
Purpose To determine whether improvement in THA-free survival across an 18-year hip arthroscopy series is attributable to progressive exclusion of high-risk patient profiles or to era-specific technical advances, and to identify the radiological selection thresholds most strongly associated with this improvement. Methods Retrospective analysis of a prospectively maintained single-surgeon database. A consecutive series of 1,051 hips operated on for FAI (2007–2025; Tönnis grades 0 to 2) was stratified into four surgical eras. The primary outcome was THA conversion. THA-free survival was estimated by the Kaplan–Meier method; predictors of conversion were identified by multivariable Cox proportional hazards regression. Results Eighty-three hips (7.9%) underwent THA conversion over a median follow-up of 53.6 months (5,939 patient-years). Five-year THA-free survival was 91.4% (95% CI 89.3–93.1%) overall and differed significantly across eras (log-rank p < 0.0001). Era II (2012–2015) had the lowest five-year survival (83.3%; 95% CI: 75.5–86.1%), corresponding to the peak prevalence of Tönnis grade ≥ 2 (29.5%) in the entire series. Progressive changes in radiological selection criteria were accompanied by a reduction in severe ALAD lesions identified intraoperatively. The prevalence of Tönnis grade ≥ 2 declined from 29.5% to 10.0% across eras. On multivariable analysis, ALAD grade (HR 2.59; 95% CI 1.58–4.27; p < 0.001), Tönnis grade (HR 2.13; 1.24–3.66; p = 0.006) and age (HR 1.06/year; p < 0.001) were independent predictors of THA conversion; era hazard ratios were non-significant after adjustment for these variables (p > 0.19). The five-year estimate for Era IV (95.9%) should be interpreted with caution given the limited follow-up in this cohort (median 30.8 months). Apparent C-index: 0.911 (95% CI 0.882–0.940); no internal validation was performed. Conclusion Improvement in THA-free survival over 18 years was closely associated with the progressive reduction in the proportion of operated patients with Tönnis grade ≥ 2. Although technical evolution occurred concurrently, era effects were substantially attenuated after adjustment for patient selection variables. Tönnis grade functions as the primary pre-operative selection variable; ALAD grade, identified intraoperatively, had the highest adjusted hazard ratio for THA conversion and reflects the consequences of pre-operative selection. These findings support the importance of pre-operative radiological selection—particularly Tönnis grade—when interpreting THA conversion rates across institutions and historical surgical series.
- 10 July 2026
- Published by Springer Nature in International Orthopaedics
- Vol. 50 (10) , 2577-2589
Patient selection refines total hip arthroplasty free survival after hip arthroscopy: an eighteen year, one thousand and fifty one hip cohort study
Purpose To determine whether improvement in THA-free survival across an 18-year hip arthroscopy series is attributable to progressive exclusion of high-risk patient profiles or to era-specific technical advances, and to identify the radiological selection thresholds most strongly associated with this improvement. Methods Retrospective analysis of a prospectively maintained single-surgeon database. A consecutive series of 1,051 hips operated on for FAI (2007–2025; Tönnis grades 0 to 2) was stratified into four surgical eras. The primary outcome was THA conversion. THA-free survival was estimated by the Kaplan–Meier method; predictors of conversion were identified by multivariable Cox proportional hazards regression. Results Eighty-three hips (7.9%) underwent THA conversion over a median follow-up of 53.6 months (5,939 patient-years). Five-year THA-free survival was 91.4% (95% CI 89.3–93.1%) overall and differed significantly across eras (log-rank p < 0.0001). Era II (2012–2015) had the lowest five-year survival (83.3%; 95% CI: 75.5–86.1%), corresponding to the peak prevalence of Tönnis grade ≥ 2 (29.5%) in the entire series. Progressive changes in radiological selection criteria were accompanied by a reduction in severe ALAD lesions identified intraoperatively. The prevalence of Tönnis grade ≥ 2 declined from 29.5% to 10.0% across eras. On multivariable analysis, ALAD grade (HR 2.59; 95% CI 1.58–4.27; p < 0.001), Tönnis grade (HR 2.13; 1.24–3.66; p = 0.006) and age (HR 1.06/year; p < 0.001) were independent predictors of THA conversion; era hazard ratios were non-significant after adjustment for these variables (p > 0.19). The five-year estimate for Era IV (95.9%) should be interpreted with caution given the limited follow-up in this cohort (median 30.8 months). Apparent C-index: 0.911 (95% CI 0.882–0.940); no internal validation was performed. Conclusion Improvement in THA-free survival over 18 years was closely associated with the progressive reduction in the proportion of operated patients with Tönnis grade ≥ 2. Although technical evolution occurred concurrently, era effects were substantially attenuated after adjustment for patient selection variables. Tönnis grade functions as the primary pre-operative selection variable; ALAD grade, identified intraoperatively, had the highest adjusted hazard ratio for THA conversion and reflects the consequences of pre-operative selection. These findings support the importance of pre-operative radiological selection—particularly Tönnis grade—when interpreting THA conversion rates across institutions and historical surgical series.